Updates in the Systemic Therapy Options for Clear and Non-Clear Cell Renal Cell Carcinoma
The expansion of treatment options included in the treatment guidelines has certainly improved outcomes of patients with advanced RCC but presents numerous clinical challenges, such as determining best choice of primary treatment for a given patient based on tumor biology and clinical characteristics and in choosing appropriate subsequent lines of treatment.
Category
- Kidney Cancer
Format
- Recorded Webcast
Credits
- 1.00 AAPA Category 1 CME credit
- 1.00 ACPE contact hours
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC contact hours
- 1.00 Participation
Clinical Considerations in Renal Cell Carcinoma: Current Evidence, Guideline Recommendations, and a View to the Future
The goal of this program is to improve the knowledge and competence of learners in the optimal management of patients with RCC.
Category
- Kidney Cancer
Format
- Recorded Webcast
Credits
- 1.75 AAPA Category 1 CME credit
- 1.75 ACPE contact hours
- 1.75 AMA PRA Category 1 Credit™
- 1.75 ANCC contact hours
- 1.75 Participation
Archived Monthly Oncology Tumor Boards: Identification and Management of Immuno-Oncology Targeted Therapy-Related Adverse Events in Renal Cell Carcinoma
The treatment landscape for renal cell carcinoma (RCC) is rapidly evolving as new data continue to emerge for novel therapy options. As new immune checkpoint inhibitor (ICI)-based combinations continue to be developed, it is critical for clinicians to recognize and effectively manage immune-related adverse events associated with the ICIs in RCC to ensure maximum benefits from the treatment.
Category
- Kidney Cancer
Format
- Recorded Webcast
Credits
- 1.00 AAPA Category 1 CME credit
- 1.00 ACPE contact hours
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC contact hours
- 1.00 CCM clock hours
- 1.00 Participation